Cargando…
Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
BACKGROUND: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. OBJECTIVES: We aimed to assess core drivers of hepatitis C medical care costs and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768202/ https://www.ncbi.nlm.nih.gov/pubmed/24032044 http://dx.doi.org/10.5812/hepatmon.6750 |
_version_ | 1782283749203902464 |
---|---|
author | Jakovljevic, Mihajlo Mijailovic, Zeljko Popovska Jovicic, Biljana Canovic, Predrag Gajovic, Olgica Jovanovic, Mirjana Petrovic, Dejan Milovanovic, Olivera Djordjevic, Natasa |
author_facet | Jakovljevic, Mihajlo Mijailovic, Zeljko Popovska Jovicic, Biljana Canovic, Predrag Gajovic, Olgica Jovanovic, Mirjana Petrovic, Dejan Milovanovic, Olivera Djordjevic, Natasa |
author_sort | Jakovljevic, Mihajlo |
collection | PubMed |
description | BACKGROUND: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. OBJECTIVES: We aimed to assess core drivers of hepatitis C medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis C virus with genotypes 1 or 4 (group I), and 2 or 3 (group II). PATIENTS AND MATERIALS: Prospective bottom-up cost-effectiveness analysis from societal perspective was conducted at Infectious Diseases Clinic, University Clinic Kragujevac, Serbia, from 2007 to 2010. There were 81 participants with hepatitis C infection, treated with peg alpha-2a interferon plus ribavirin for 48 or 24 weeks. Economic data acquired were direct inpatient medical costs, outpatient drug acquisition costs, and indirect costs calculated through human capital approach. RESULTS: Total costs were significantly higher (P = 0.035) in group I (mean ± SD: 12,751.54 ± 5,588.06) compared to group II (mean ± SD: 10,580.57 ± 3,973.02). In addition, both direct (P = 0.039) and indirect (P < 0.001) costs separately were significantly higher in group I compared to group II. Separate comparison within direct costs revealed higher total cost of medical care (P = 0.024) in first compared to second genotype group, while the similar tendency was observed for total drug acquisition (P = 0.072). CONCLUSION: HCV genotypes 1 and 4 cause more severe clinical course require more care and thus incur higher expenses compared to HCV 2 and 3 genotypes. Policy makers should consider willingness to pay threshold differentially depending upon HCV viral genotype detected. |
format | Online Article Text |
id | pubmed-3768202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-37682022013-09-12 Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients Jakovljevic, Mihajlo Mijailovic, Zeljko Popovska Jovicic, Biljana Canovic, Predrag Gajovic, Olgica Jovanovic, Mirjana Petrovic, Dejan Milovanovic, Olivera Djordjevic, Natasa Hepat Mon Research Article BACKGROUND: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. OBJECTIVES: We aimed to assess core drivers of hepatitis C medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis C virus with genotypes 1 or 4 (group I), and 2 or 3 (group II). PATIENTS AND MATERIALS: Prospective bottom-up cost-effectiveness analysis from societal perspective was conducted at Infectious Diseases Clinic, University Clinic Kragujevac, Serbia, from 2007 to 2010. There were 81 participants with hepatitis C infection, treated with peg alpha-2a interferon plus ribavirin for 48 or 24 weeks. Economic data acquired were direct inpatient medical costs, outpatient drug acquisition costs, and indirect costs calculated through human capital approach. RESULTS: Total costs were significantly higher (P = 0.035) in group I (mean ± SD: 12,751.54 ± 5,588.06) compared to group II (mean ± SD: 10,580.57 ± 3,973.02). In addition, both direct (P = 0.039) and indirect (P < 0.001) costs separately were significantly higher in group I compared to group II. Separate comparison within direct costs revealed higher total cost of medical care (P = 0.024) in first compared to second genotype group, while the similar tendency was observed for total drug acquisition (P = 0.072). CONCLUSION: HCV genotypes 1 and 4 cause more severe clinical course require more care and thus incur higher expenses compared to HCV 2 and 3 genotypes. Policy makers should consider willingness to pay threshold differentially depending upon HCV viral genotype detected. Kowsar 2013-06-19 /pmc/articles/PMC3768202/ /pubmed/24032044 http://dx.doi.org/10.5812/hepatmon.6750 Text en Copyright © 2013, Kowsar Corp. http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jakovljevic, Mihajlo Mijailovic, Zeljko Popovska Jovicic, Biljana Canovic, Predrag Gajovic, Olgica Jovanovic, Mirjana Petrovic, Dejan Milovanovic, Olivera Djordjevic, Natasa Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients |
title | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients |
title_full | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients |
title_fullStr | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients |
title_full_unstemmed | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients |
title_short | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients |
title_sort | assessment of viral genotype impact to the cost-effectiveness and overall costs of care for peg-interferon-2α + ribavirine treated chronic hepatitis c patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768202/ https://www.ncbi.nlm.nih.gov/pubmed/24032044 http://dx.doi.org/10.5812/hepatmon.6750 |
work_keys_str_mv | AT jakovljevicmihajlo assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT mijailoviczeljko assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT popovskajovicicbiljana assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT canovicpredrag assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT gajovicolgica assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT jovanovicmirjana assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT petrovicdejan assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT milovanovicolivera assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients AT djordjevicnatasa assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients |